Barclays’s Generate Biomedicines GENB Stock Holding History

Barclays’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97M	Buy	116,902 +46,008	+65%	+$627K	﹤0.01%	2346
2026 Q1	$886K	Buy	+70,894	New	+$866K	﹤0.01%	2825

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Barclays's GENB Position: Q2 2026 in Review

Barclays increased its Generate Biomedicines (GENB) stake by 65% in Q2 2026, buying an estimated $627K and bringing the position to 116,902 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

Barclays first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Barclays held 116,902 shares of Generate Biomedicines worth $1.97M as of Q2 2026.
Barclays bought 46,008 Generate Biomedicines shares in Q2 2026, an estimated $627K.
Generate Biomedicines made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2346 holding.
Barclays first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.